Who are the long-term survivors of high grade serous ovarian cancer?

Gynecologic Oncology

Volumn 148, Issue 1, 2018, Pages 204-212

  Hoppenot, Claire ^a   Eckert, Mark A ^a   Tienda, Samantha M ^a   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemo sensitivity; Gene expression profiling; Long term survivor; Ovarian cancer; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT;

ASCITES; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVOR; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; CYTOSKELETON; GENE EXPRESSION; GENOMICS; GERMLINE MUTATION; HUMAN; LONG TERM SURVIVAL; NUTRIENT; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; CYSTADENOCARCINOMA; FEMALE; GENETICS; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY;

CANCER SURVIVORS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 85034422487     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.10.032     Document Type: Review

References (69)

1. Baldwin, L.A., Huang, B., Miller, R.W., Tucker, T., Goodrich, S.T., Podzielinski, I., et al. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 120 (2012), 612–618.
2. Gockley, A., Melamed, A., Bregar, A.J., Clemmer, J.T., Birrer, M., Schorge, J.O., et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet. Gynecol. 129 (2017), 439–447.
3. Cress, R.D., Chen, Y.S., Morris, C.R., Petersen, M., Leiserowitz, G.S., Characteristics of long-term survivors of epithelial ovarian cancer. Obstet. Gynecol. 126 (2015), 491–497.
4. Akeson, M., Jakobsen, A.M., Zetterqvist, B.M., Holmberg, E., Brannstrom, M., Horvath, G., A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int. J. Gynecol. Cancer 19 (2009), 116–123.
5. Horowitz, N.S., Miller, A., Rungruang, B., Richard, S.D., Rodriguez, N., Bookman, M.A., et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J. Clin. Oncol. 33 (2015), 937–943.
6. Matz, M., Coleman, M.P., Carreira, H., Salmeron, D., Chirlaque, M.D., Allemani, C., et al. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol. Oncol. 144 (2017), 396–404.
7. Du Bois, A., Lück, H.J., Meier, W., Adams, H.P., Möbus, V., Costa, S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003), 1320–1330.
8. Vergote, I., Troupe, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363 (2010), 943–953.
9. Wimberger, P., Wehling, M., Lehmann, N., Kimmig, R., Schmalfeldt, B., Burges, A., et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann. Surg. Oncol. 17 (2010), 1642–1648.
10. Winter, W.E., Maxwell, L., Tian, C., Carlson, J.W., Ozols, R.F., Rose, P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007), 3621–3627.
11. Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimmae, H., Kimura, E., et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG3016): a randomised, controlled open-label trial. Lancet Oncol. 14 (2013), 1020–1026.
12. Barlin, J.N., Jelinic, P., Olvera, N., Bogomolniy, F., Bisogna, M., Dao, F., et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol. Oncol. 128 (2013), 512–517.
13. Iwase, H., Takada, T., Iitsuka, C., Nomura, H., Abe, A., Taniguchi, T., et al. Clinical features of long-term survivors of recurrent epithelial ovarian cancer. Int. J. Clin. Oncol. 20 (2015), 143–149.
14. Jochumsen, K.M., Tan, Q., Hogdall, E.V., Hogdall, C., Kjaer, S.K., Blaakaer, J., et al. Gene expression profiles as prognostic markers in women with ovarian cancer. Int. J. Gynecol. Cancer 19 (2009), 1205–1213.
15. Kotsopoulos, J., Rosen, B., Fan, I., Moody, J., McLaughlin, J.R., Risch, H., et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol. Oncol. 140 (2016), 42–47.
16. Nikas, J.B., Boylan, K.L., Skubitz, A.P., Low, W.C., Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informat. 10 (2011), 233–247.
17. Lambert, H.E., Gregory, W.M., Nelstrop, A.E., Rustin, G.J., Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int. J. Gynecol. Cancer 14 (2004), 772–778.
18. Du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of prospectively randomized phase 3 multicenter trials. Cancer 115 (2009), 1234–1244.
19. Kaern, J., Aghmesheh, M., Nesland, J.M., Danielsen, H.E., Sandstad, B., Friedlander, M., et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?. Int. J. Gynecol. Cancer 15 (2005), 1014–1022.
20. Rubin, S.C., Randall, T.C., Armstrong, K.A., Chi, D.S., Hoskins, W.J., Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet. Gynecol. 93 (1999), 21–24.
21. Hoskins, W.J., Bundy, B.N., Thigpen, J.T., Omura, G.A., The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. 47 (1992), 159–166.
22. Tewari, D., Java, J.J., Salani, R., Armstrong, D.K., Markman, M., Herzog, T., et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 33 (2015), 1460–1466.
23. Dao, F., Schlappe, B.A., Tseng, J., Lester, J., Nick, A.M., Lutgendorf, S.K., et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol. Oncol. 141 (2016), 260–263.
24. Kajiyama, H., Shibata, K., Mizuno, M., Umezu, T., Suzuki, S., Yamamoto, E., et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?. Int. J. Gynecol. Cancer 22 (2012), 394–399.
25. Chi, D.S., McCaughty, K., Diaz, J.P., Huh, J., Schwabenbauer, S., Hummer, A., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006), 1933–1939.
26. Suh, D.H., Kim, H.S., Chang, S.J., Bristow, R.E., Surgical management of recurrent ovarian cancer. Gynecol. Oncol. 142 (2016), 357–367.
27. Petrillo, M., Fagotti, A., Ferrandina, G., Fanfani, F., Costantini, B., Vizzielli, G., et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol. Oncol. 131 (2013), 36–41.
28. Classe, J.M., Jaffre, I., Frenel, J.S., Bordes, V., Dejode, M., Dravet, F., et al. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. Eur. J. Surg. Oncol. 37 (2011), 971–977.
29. Petrillo, M., De Iaco, P., Cianci, S., Perrone, M., Costantini, B., Ronsini, C., et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann. Surg. Oncol. 23 (2016), 1660–1665.
30. Legge, F., Petrillo, M., Adamo, V., Pisconti, S., Scambia, G., Ferrandina, G., Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer, 8, 2008, 367.
31. Kim, S.J., Rosen, B., Fan, I., Ivanova, A., McLaughlin, J.R., Risch, H., et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br. J. Cancer 116 (2017), 964–971.
32. Eeles, R., Morden, J.P., Gore, M., Mansi, J., Glees, J., Wenczl, M., et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 33 (2015), 4138–4144.
33. Walsh, T., Casadei, S., Lee, M.K., Pennil, C.C., Nord, A.S., Thornton, A.M., et al. Mutations in 12 genes for inherited ovarian, fallopian tube and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 18032–18037.
34. Rubin, S.C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M.A., LiVolsi, V.A., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335 (1996), 1413–1416.
35. Bolton, K.L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S.J., Karlan, B.Y., et al. Association between BRCA1 and BRCA 2 mutations and survival in women with invasive epithelial ovarian cancer. J. Am. Med. Assoc. 307 (2012), 382–390.
36. Alsop, K., Fereday, S., Meldrum, C., DeFazio, A., Emmanuel, C., George, J., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J. Clin. Oncol., 2012, 1–11.
37. Candido-dos-Reis, F.J., Song, H., Goode, E.L., Cunningham, J.M., Fridley, B.L., Larson, M.C., et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin. Cancer Res. 21 (2015), 652–657.
38. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:8 (2014), 852–861.
39. Watson, P., Butzow, R., Lynch, H.T., Mecklin, J.P., Jarvinen, H.J., Vasen, H.F., et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 82 (2001), 223–228.
40. Norquist, B.M., Harrell, M.I., Brady, M.F., Walsh, T., Lee, M.K., Gulsuner, S., et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2 (2016), 482–490.
41. Pennington, K.P., Walsh, T., Harrell, M.I., Lee, M.K., Pennil, C.C., Rendi, M.H., et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20 (2014), 764–775.
42. Quinn, J.E., James, C.R., Stewart, G.E., BRCA1 mRNA expression levels predict for overall survival an ovarian cancer after chemotherapy. Clin. Cancer Res. 13 (2007), 7413–7420.
43. The Cancer Genome Atlas N, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
44. Moore, K.N., Mannel, R.S., Is the NCI MATCH trial a match for gynecologic oncology?. Gynecol. Oncol. 140 (2016), 161–166.
45. Spentzos, D., Levine, D.A., Ramoni, M.F., Joseph, M., Gu, X., Boyd, J., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22 (2004), 4700–4710.
46. Spentzos, D., Levine, D.A., Kolia, S., Otu, H., Boyd, J., Libermann, T.A., et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J. Clin. Oncol. 23 (2005), 7911–7918.
47. Donnenberg, V.S., Meyer, E.M., Donnenberg, A.D., Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells. Methods Mol. Biol. 568 (2009), 261–279.
48. Berchuck, A., Iversen, E.S., Lancaster, J.M., Pittman, J., Luo, J., Lee, P., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin. Cancer Res. 11 (2005), 3686–3696.
49. Tracey, L., Villuendas, R., Ortiz, P., Dopazo, A., Spiteri, I., Lombardia, L., et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am. J. Pathol. 161 (2002), 1825–1837.
50. Berchuck, A., Iversen, E.S., Luo, J., Clarke, J.P., Horne, H., Levine, D.A., et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin. Cancer Res. 15 (2009), 2448–2455.
51. Partheen, K., Levan, K., Osterberg, L., Horvath, G., Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur. J. Cancer 42 (2006), 2846–2854.
52. Verhaak, R.G.W., Tarnayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123 (2013), 517–525.
53. Hwang, W.T., Adams, S.F., Tahirovic, E., Hagemann, I.S., Coukos, G., Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124 (2012), 192–198.
54. Bosmuller, H.C., Wagner, P., Peper, J.K., Schuster, H., Pham, D.L., Greif, K., et al. Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int. J. Gynecol. Cancer 26 (2016), 671–679.
55. Kroeger, D.R., Milne, K., Nelson, B.H., Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22 (2016), 3005–3015.
56. Webb, J.R., Milne, K., Kroeger, D.R., Nelson, B.H., PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141 (2016), 293–302.
57. Darb-Esfahani, S., Kunze, C.A., Kulbe, H., Sehouli, J., Wienert, S., Lindner, J., et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7 (2016), 1486–1499.
58. Chan, J.K., Loizzi, V., Lin, Y.G., Osann, K., Brewster, W.R., DiSaia, P.J., Stages, I.I.I., IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet. Gynecol. 102 (2003), 156–161.
59. Asher, V., Lee, J., Bali, A., Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med. Oncol. 29 (2012), 2005–2009.
60. Huang, H., Li, Y.J., Lan, C.Y., Huang, Q.D., Feng, Y.L., Huang, Y.W., et al. Clinical significance of ascites in epithelial ovarian cancer. Neoplasma 60 (2013), 546–552.
61. Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Trimble, E.L., Montz, F.J., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002), 1248–1259.
62. Bar, D., Lavie, O., Stein, N., Feferkorn, I., Shai, A., The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 207 (2016), 227–231.
63. Thigpen, T., Brady, M.F., Omura, G.A., Creasman, W.T., McGuire, W.P., Hoskins, W.J., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71 (1993), 606–614.
64. Bamias, A., Psaltopoulou, T., Sotiropoulou, M., Haidopoulos, D., Lianos, E., Bournakis, E., et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116 (2010), 1462–1468.
65. Xu, X., Wang, Y., Wang, F., Jia, L., Zhou, Y., Deng, F., et al. Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. J. Ovarian Res., 6, 2013, 31.
66. Stone, R.L., Nick, A.M., McNeish, I.A., Balkwill, F.R., Han, H.D., Bottsford-Miller, J., et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366 (2012), 610–618.
67. Ataseven, B., du Bois, A., Reinthaller, A., Traut, A., Heitz, F., Aust, S., et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol. Oncol. 138 (2015), 560–565.
68. Cass, I., Baldwin, R.L., Varkey, T., Moslehi, R., Narod, S.A., Karlan, B.Y., Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003), 2187–2195.
69. Milam, M.R., Harrell, R., Bassett, R., Parker, L.P., Metzinger, D.S., Ramirez, P.T., Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report. Int. J. Gynecol. Cancer 21 (2011), 475–477.